SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0001193125-18-135231
Filing Date
2018-04-26
Accepted
2018-04-26 17:25:55
Documents
7
Effectiveness Date
2018-04-26

Document Format Files

Seq Description Document Type Size
1 DEFA14A d578334ddefa14a.htm DEFA14A 36118
2 GRAPHIC g578334code1.jpg GRAPHIC 3734
3 GRAPHIC g578334code2.jpg GRAPHIC 3912
4 GRAPHIC g578334code3.jpg GRAPHIC 3875
5 GRAPHIC g578334xxx1.jpg GRAPHIC 3150
6 GRAPHIC g578334xxx2.jpg GRAPHIC 3158
7 GRAPHIC g578334xxx3.jpg GRAPHIC 3215
  Complete submission text file 0001193125-18-135231.txt   67069
Mailing Address 350 CAMBRIDGE AVE SUITE 350 PALO ALTO CA 94306
Business Address 350 CAMBRIDGE AVE SUITE 350 PALO ALTO CA 94306 650-279-9845
Eiger BioPharmaceuticals, Inc. (Filer) CIK: 0001305253 (see all company filings)

IRS No.: 361004130 | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 001-36183 | Film No.: 18779853
SIC: 2836 Biological Products, (No Diagnostic Substances)